Announced details
Assistance in diagnosing influenza virus infection, rapid diagnosis at medical institutions, and POCT (point-of-care testing)
Detects and differentiates influenza A and B in approximately 15 minutes. Detection sensitivity has been improved and measurement time shortened compared with the previous product.
Ministry of Health, Labour and Welfare (marketing authorization as an in vitro diagnostic medical device)
Suggested delivery price: ¥36,000 (excluding tax; 24 tests)
The impact on the earnings forecast for the fiscal year ending March 2027 is expected to be minimal.
The company does not address Contract Value.
Recommendations for the Effective Use of Influenza Nucleic Acid Detection Testing (2023), Committee on Genetic Testing for Infectious Diseases, Japanese Association for Infectious Diseases; Committee for the Study of New Tests in the Infectious Diseases Field, Japanese Association for Clinical Microbiology
| Item | Details |
|---|---|
| Names of Products / Services Covered | GeneSoC FluA/B Detection Kit, GeneSoC mini 2 genetic analyzer, GeneSoC mini genetic analyzer |
| Offering price | Suggested delivery price: ¥36,000 (excluding tax; 24 tests) |
| Launch date | Launched on 11 September 2026 (actual) |
| Applicable area | Assistance in diagnosing influenza virus infection, rapid diagnosis at medical institutions, and POCT (point-of-care testing) |
| Awarding / certifying body | Ministry of Health, Labour and Welfare (marketing authorization as an in vitro diagnostic medical device) |
| Quantitative Effects | Detects and differentiates influenza A and B in approximately 15 minutes. Detection sensitivity has been improved and measurement time shortened compared with the previous product. |
| Impact on Business Performance | The impact on the earnings forecast for the fiscal year ending March 2027 is expected to be minimal. |
| Source | Recommendations for the Effective Use of Influenza Nucleic Acid Detection Testing (2023), Committee on Genetic Testing for Infectious Diseases, Japanese Association for Infectious Diseases; Committee for the Study of New Tests in the Infectious Diseases Field, Japanese Association for Clinical Microbiology |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To assist in diagnosing influenza virus infection and contribute to rapid diagnosis. The company states that, compared with the previous product, it has improved detection sensitivity and shortened measurement time.